Lawrence E Morris
Overview
Explore the profile of Lawrence E Morris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bashey S, Solomon S, Zhang X, Morris L, Holland H, Bachier L, et al.
Bone Marrow Transplant
. 2024 Sep;
59(12):1783-1785.
PMID: 39300248
No abstract available.
2.
Solh M, Aubrey M, Zhang X, Bashey A, Freed B, Roark C, et al.
Bone Marrow Transplant
. 2024 Jul;
59(10):1433-1439.
PMID: 39085372
Graft versus tumor relies on tumor-associated antigens (TAAs) that are presented to donor T cells via human leukocyte antigens (HLAs). The HLA evolutionary divergence (HED) between alleles of a single...
3.
Solomon S, Bachier-Rodriguez L, Bashey A, Zhang X, Jackson K, Holland H, et al.
Transplant Cell Ther
. 2024 Jun;
30(9):903.e1-903.e9.
PMID: 38879167
Following conventional graft-versus-host disease (GVHD) prophylaxis, the development of acute and/or chronic GVHD is associated with lower relapse rates. However, the effects of GVHD on relapse and non-relapse mortality following...
4.
Solomon S, Aubrey M, Bachier-Rodriguez L, Solh M, Jackson K, Zhang X, et al.
Transplant Cell Ther
. 2024 Apr;
30(6):608.e1-608.e10.
PMID: 38561140
The presence of an HLA-DPB1 nonpermissive mismatch (NPMM) by the TCE-3 model has been associated with improved survival following haploidentical donor transplantation (HIDT) using post-transplantation cyclophosphamide (PTCy). With the development...
5.
Solh M, Bashey A, Zhang X, Holland H, Bachier-Rdriguez L, Morris L, et al.
Transplant Cell Ther
. 2024 Mar;
30(6):607.e1-607.e8.
PMID: 38552844
The development of chronic graft-versus-host disease (GVHD) in 1-year survivors after matched related or unrelated hematopoietic cell transplantation was shown to be associated with higher nonrelapse mortality (NRM) and worse...
6.
Bashey S, Solomon S, Zhang X, Morris L, Holland H, Bachier L, et al.
Bone Marrow Transplant
. 2024 Jan;
59(4):564-565.
PMID: 38263393
No abstract available.
7.
Solomon S, Solh M, Morris L, Holland H, Bachier-Rodriguez L, Zhang X, et al.
Blood Adv
. 2023 Jun;
7(18):5215-5224.
PMID: 37379271
Allogeneic transplant remains the best postremission therapy for patients with nonfavorable risk acute myeloid leukemia (AML). However, some patients are ineligible because of psychosocial barriers, such as lack of appropriate...
8.
Bashey A, Zhang X, Morris L, Holland H, Bachier-Rodriguez L, Solomon S, et al.
Blood Adv
. 2023 Mar;
7(15):3816-3823.
PMID: 36961350
Few patients with nonfavorable risk (NFR) acute leukemia and myeloid dysplasia syndrome (AL/MDS) undergo allogeneic transplantation (HCT). We assessed whether this could be improved by integrating HCT/leukemia care and the...
9.
Solh M, Farnham C, Solomon S, Bashey A, Morris L, Holland H, et al.
Bone Marrow Transplant
. 2022 Nov;
58(2):168-174.
PMID: 36352015
Steroid refractory acute graft-versus-host disease (SR aGvHD) is a major limitation of successful allogeneic hematopoietic stem cell transplantation (HSCT). Extracorporeal photopheresis (ECP) has been used to treat SR aGvHD effectively...
10.
Solomon S, Aubrey M, Zhang X, Jackson K, Roark C, Freed B, et al.
Transplant Cell Ther
. 2022 Jul;
28(9):601.e1-601.e8.
PMID: 35788088
The role of NK cell alloreactivity on outcomes after T cell-replete haploidentical donor transplantation (HIDT) remains uncertain. After transplantation, newly formed NK cells are licensed through interactions of donor inhibitory...